Skip to content

Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer

Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02944721
Acronym
DOLORISKSEIN
Enrollment
0
Registered
2016-10-26
Start date
2016-11-30
Completion date
2021-04-30
Last updated
2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Neuropathic Pain

Brief summary

The aim of the study is to establish the genetic, neurophysiological and psychological phenotype of the patients presenting a persistent neuropathic pain after surgery of the breast cancer, by comparing the neuropathic painful patients with the not painful and with the not neuropathic painful . This will be realized on a transverse cohort (Seintinellecohort) and confirmed on a forward-looking longitudinal cohort.

Interventions

GENETICGenetical analyses
OTHERChronic pain identification questionnaires
OTHERNeurophysiological and psychophysical evaluations
OTHERQuality of life questionnaires

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For both arms: Inclusion Criteria: * Women over 18 years * Having given a written consent form * Affiliated to the social security scheme * French language (read, written and spoken) * Accepting the principle of the study and able to respect the conditions of the study.

Exclusion criteria

* Other cancer or AIDS in evolution * Bilateral Mastectomy * Presence of chronic pain before the intervention for breast cancer, * occupational accident, dispute or search for compensation * Previous surgery on the same territory * Peripheral neurological pathology or central (brain damage, multiple sclerosis) susceptible to interfere with the evaluation of the post-operative pain * Heavy psychiatric histories: psychosis, severe depression having motivated a hospitalization, a suicide attempt * Current major depressive episode at the time of the evaluation (cf. criterion diagnosis of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) * Abuse of drug or psychoactive substance (cf. definition of the DSM-5) during the last six months; cognitive disorders (MMSE 24/30) or psychological incompatible with the respect and/or the understanding of the protocol * Patients participating in another protocol of biomedical research. For longitudinal study: Inclusion Criteria: * Patients who can be followed during the total duration of the study ( 12 months) for the longitudinal arm of the forward-looking study * Patients that must be operated for one of the two types of surgery: preservative surgery or mastectomy for breast cancer with ganglionic cleaning out * Chemotherapy or radiotherapy before the surgery

Design outcomes

Primary

MeasureTime frameDescription
Correlation coefficient between patients profile and type of pain13 months maxThe genetic profile will be determined from a biological sample of blood taken at the willing patients. This analysis will include: an analysis of candidate genes, an analysis piece-genomics genome-wide association (GWAS) and newer techniques of sequencing of whole exome sequencing allowing to study variants with low and high impact. The psychological profile will be determined by tests estimating the affect, the suffering, the capacities of management of the pain, the emotional regulation and the neuropsychological tests . The neurophysiological profile will be determined by an evaluation quantified by the sensibility, the tests of painful conditioning stimulation, and the analysis of the excitability of nerve fibers.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026